Resources

Transition from NDA to Biosimlars and FDA guidance on biosimilar Naming

Speaker
9/26/2016
Hotel Taj Krishna
Hyderabad,
India
Transition from NDA to Biosimlars and FDA guidance on biosimilar Naming